Exisulind: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
No edit summary |
||
| Line 49: | Line 49: | ||
{{Antineoplastic-drug-stub}} | {{Antineoplastic-drug-stub}} | ||
<gallery> | <gallery> | ||
File:Exisulind structure.svg|Exisulind | File:Exisulind structure.svg|Exisulind | ||
</gallery> | </gallery> | ||
Latest revision as of 21:02, 16 March 2025
| Chemical Compound | |
|---|---|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider ID | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Properties | |
| Chemical Formula | |
| Molar Mass | |
| Appearance | |
| Density | |
| Melting Point | |
| Boiling Point | |
| Hazards | |
| GHS Pictograms | [[File:|50px]] |
| GHS Signal Word | |
| GHS Hazard Statements | |
| NFPA 704 | [[File:|50px]] |
| References | |
Exisulind (tentative trade name Aptosyn) is an antineoplastic agent. It acts by inhibiting the enzyme cyclic guanosine monophosphate phosphodiesterase type 5 (EC 3.1.4.17 ).<ref>,
Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone., Drugs in R&D, Vol. 5(Issue: 4), pp. 220–6, PMID: 15230629,</ref> It is the sulfone derivative of sulindac, an NSAID. Unlike sulindac, it has known effects on prostaglandin synthesis.<ref>, Phase I trial of Exisulind (Sulindac Sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis., Clinical Cancer Research, Vol. 6(Issue: 1), pp. 78–89, PMID: 10656435,</ref> It was developed as the potential treatment of several conditions including familial adenomatous polyposis (FAP), precancerous sporadic colonic polyps, cervical dysplasia and the prevention of tumor recurrence in prostate and breast cancer.<ref>, Exisulind Cell Pathways., Current Opinion in Investigational Drugs, Vol. 1(Issue: 3), pp. 386–91, PMID: 11249724,</ref> Exisulind inhibits the enzyme cGMP-PDE, overexpressed in precancerous and cancerous colorectal cells, and induces apoptosis in such cells with minimal effects on normal cells. This apoptotic effect is independent of COX-1 or COX-2 inhibition, p53, Bcl-2, or cell cycle arrest. Preclinical evidence suggests that exisulind also inhibits angiogenesis.<ref>, Inhibition of Angiogenesis by Sulindac and its Sulfone Metabolite (FGN-1): a Potential Mechanism for Their Antineoplastic Properties., International Journal of Tissue Reactions, Vol. 20(Issue: 3), pp. 85–9, PMID: 9894180,</ref>
See also[edit]
References[edit]
<references group="" responsive="1"></references>


